NCT02494570 2023-04-07
AMPECT
Aadi Bioscience, Inc.
Phase 2 Completed
Clinical Trials
3 trialsNCT03817515 2022-03-16
Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation
Aadi Bioscience, Inc.
Approved for marketing
NCT01690871 2013-08-02
A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa
Novartis
Phase 2 Withdrawn